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Abstract 
This review updates the recent advances and applications of three prominent synchrotron 
radiation techniques, microprobe X-ray fluorescent spectroscopy/imaging, X-ray absorption 
spectroscopy and infrared microspectroscopy, and highlights how these tools are useful to the 
medicinal chemist.  A brief description of the principles of the techniques is given with 
emphasis on the advantages of using synchrotron radiation-based instrumentation rather than 
instruments using typical laboratory radiation sources.  This review focuses on a number of 
recent applications of these techniques to solve inorganic medicinal chemistry problems, 
focusing on studies of cellular uptake, distribution and biotransformation of established and 
potential therapeutic agents.  The importance of using these synchrotron-based techniques to 
assist the development, or validate the chemistry behind, drug design is discussed.   
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Introduction 
The cellular uptake, distribution and biotransformations associated with administration of a 
therapeutic agent are all crucial information for the medicinal chemist as they assist the 
design, understanding and development of a pharmaceutical.  Importantly, the inorganic 
medicinal chemist can exploit the detection sensitivity and capabilities that synchrotron 
radiation techniques such as X-ray fluorescence (XRF) spectroscopy and X-ray absorption 
spectroscopy (XAS) possess for the detection and characterisation, respectively, of trace 
metals/metalloids associated with metallo-/metalloid- containing therapeutics in biological 
systems or fluids.  While there are exceedingly sensitive analytical techniques available for 
this use such as high performance liquid chromatography (HPLC), graphite furnace atomic 
absorption spectrophotometry (GFAAS) and inductively-coupled plasma-mass spectrometry 
(ICP-MS),[1-2] these techniques fail to provide crucial spatial information regarding a drug in 
a tissue or cell.  Also, in most cases the sample preparation (such as solvent extractions or 
acid digestion) associated with these techniques does not preserve important 
features/information such as the biological structure and/or the chemical speciation/structure 
of the drug or its metabolites.[1-2] As such, synchrotron radiation techniques such as 
microprobe XRF and XAS, offer unique advantages over laboratory-based techniques, as will 
be discussed in the following sections.  While there are other microprobe techniques capable 
of relatively sensitive imaging, these are not the focus of this review and the reader is referred 
to the following references for information on these techniques.[3-5]  In addition to XRF and 
XAS analysis of biological systems, synchrotron radiation-Fourier transform infrared (SR-
FTIR) microspectroscopy has recently shown promise for rapid, high quality and high 
throughput analysis of biological samples, particularly cell samples. The latest applications of 
this technique for monitoring biomolecular changes associated with drug administration will 
be described.   
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Microprobe X-Ray Fluorescence Imaging 
XRF spectroscopy is an analytical technique which involves the detection of emitted 
characteristic X-rays following excitation of the elements within the sample.[6-9]  While 
electron, particle (protons or alpha particles), or X-ray beams can be employed as the exciting 
source for this analysis, the use of X-ray beams (from a synchrotron source) has been 
instrumental in the advancement of the technique in the area of microprobe XRF imaging for 
inorganic medicinal chemistry purposes.[5,8,10-11]  Synchrotron radiation X-ray fluorescence 
(SRXRF) spectroscopy, also known as synchrotron radiation induced X-ray emission 
(SRIXE) spectroscopy, has become competitive with the earlier microprobe and nanoprobe 
techniques following the development of X-ray focusing devices, such as the Kirkpatrick-
Baez (KB) mirror and the zone plate, that are capable of micron and submicron resolution, 
respectively.[12-15]  There are two important features that contribute to the superb elemental 
sensitivities of microprobe SRXRF: (i) the absence of the continuum (bremsstrahlung) 
background radiation that is a feature of spectra obtained from charged particle beams, and 
(ii) the increased X-ray flux on the sample associated with the use of third generation 
synchrotron facilities.[5,16-18]  Detection sensitivities have been reported in the ppb range, with 
values of 1017g - 1014 g (depending on the particular element) cited for analysis of samples 
as small as individual mammalian (or even bacterial) cells.[6,16-22]    
The physical process of XRF spectroscopy (Figure 1) involves the use of a beam that 
possesses an energy high enough to excite the atoms of all the elements of interest (i.e., 
higher than the binding energy of the core electron of the element, generally K and L 
shells).[6-7] When the beam strikes the sample and a core electron is ejected into the 
continuum, an unstable ion is produced.  An electron, from an outer energy level, drops down 
to fill the resultant vacancy and this is accompanied by the emission of an X-ray photon.  The 
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energy of the X-ray photon is equal to the energy difference in the initial and final states of 
the transferred electron.[6-7]  Since the electron transitions obey specific selection rules, the 
differences in energy levels are discrete and characteristic for a particular element, giving rise 
to characteristic X-rays that provide a unique identification for each element.[6,10,23]  Binding 
energies and characteristic X-rays are documented for almost all elements (Z95) of the 
periodic table.[23]  Most commonly, K and L lines are studied since the M and N line series 
are often masked by competing Auger interference.[6,8]  
While XRF spectra can be collected at point locations within a sample, it is the mapping 
capabilities that are useful for studying the targeting action and metabolism of inorganic 
therapeutic agents within biological samples ranging from tumours to individual cancer 
cells.[3-4,24]  The elemental imaging is performed by using a high precision XYZ motorized 
stage (up to 0.05 microns spatial resolution) that scans the sample in a rastor pattern in the 
path of the spatially fixed beam.[8,25-26]  The sample is housed in a He or N2 atmosphere to 
reduce the measurable component of Ar which is found in air.  This is important for analysis 
of biological samples since the spectral position of the Ar K-shell fluorescence peak occurs in 
the region of P, S, Cl and K which are important endogenous elements.[8]  Of the two gases, 
however, He is the preferred gas given that there will be close to no absorption of the emitted 
X-rays, whilst N2 gas will absorb significantly (40% of 2 keV X-rays) in a 1-cm path.
[27]   
Microprobe XRF imaging of a metal-containing drug within a biological sample 
directly probes the metal based on the fundamental nature of the element.  As such there is no 
need to tag or radiolabel the drug. [6,28]  In the instance of detecting intracellular elements that 
are also endogenous, it is important that the introduced element is at significantly higher 
concentrations than in the control.  Various sample forms can be studied depending on the 
required outcome.[8]  Minimal sample preparation/interference is preferred when microprobe 
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SRXRF is combined with other techniques such as microprobe XAS or SRFTIR 
microspectroscopy, so that the integrity of the chemical structures within the sample are 
maintained.  Samples such as cells or tissue can be grown or deposited on spectroscopically 
silent substrates, ideally silicon nitride membranes, formvar foils or polycarbonate foils [8,28-
29].  Often rapid freezing/cryofixation and freeze-drying of tissue or cells are the protocols 
used for preparation of samples associated with XAS analysis.[8,15,19,28,30-34]  Microprobe 
SRXRF analysis has also been performed on whole cells grown on silicon nitride membranes 
following fixation using glutaraldehyde or methanol.[35-36] For elements/drugs that possess 
reasonably strong interactions with intracellular biomolecules, thin-section analysis is 
beneficial as it facilitates high resolution imaging which is required for differentiation of 
organelles and provides confirmation of cell membrane penetration of the drug.  The protocol 
for preparation of thin sections includes chemical fixation (e.g., the use of glutaraldehyde in 
preference to formalin), dehydration, and resin infiltration. [8,28,32,34,37]  The procedure is 
similar to that used for preparation of samples for transmission electron microscopy since it 
preserves the ultrastructure of the sample.[8,28,32,37]  Details of these procedures are described 
in the referenced publications.[8,28,32,37]  Unfortunately, no procedure for preparation of whole 
or thin-sectioned cells is free of uncertainty, which is why hydration and cryo-analysis, in the 
form of X-ray microtomography promises to be the desired micro-imaging technique in the 
future (see later Section).  
Platinum-Containing Anti-Cancer Agents 
Microprobe SRXRF imaging has been successfully used to probe the action of established 
and potential anti-cancer drugs.[26,38]  One of the most studied class of drugs includes the 
platinum-containing drugs.  This is unsurprising due to the therapeutic significance of 
cisplatin, carboplatin and oxaliplatin which are used in the treatment regimes of more than 
half of all cancer patients receiving chemotherapy.[38-39]   
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Since the Pt L peaks (Pt L1 = 9.44 keV, Pt L2 = 9.361 keV) coexist with that of the 
Zn K peak (Zn K1 = 9.572 keV), there are two approaches to the analysis of Pt in biological 
samples.[26,38]  The first is the estimation of the Zn K contribution to the Pt L based on the 
known ratio of the Zn K peaks to the Zn K peak, followed by the subtraction of this value 
from the Pt L peaks.
[26]  The second approach is to perform the experiment at a higher 
energy (13.6 keV) that includes the Pt L peaks in the emitted X-rays and use these to 
estimate the Pt concentration.[38]  
Microprobe SRXRF studies of cisplatin-treated A2780 ovarian carcinoma cells revealed 
predominant localisation of Pt in the nucleus with a small amount in the cytoplasm following 
24 h exposure.[33] The uptake of Pt(II) and Pt(IV) potential anti-cancer agents by the A2780 
cells with the metallointercalator, cis-[PtCl2(2-[(3-aminopropyl)amino]-9,10-anthracene-
dione)(NH3)], revealed a high colocalisation of Pt and P maps which was attributed to Pt 
localisation in the cell nucleus.[38]  A study of Br-labeled Pt(II) and Pt(IV)-treated cells was 
performed to probe the mechanisms of Pt anti-cancer activity.  In the first instance, one of the 
amine ligands of cisplatin was substituted with a 3-bromopyridine ligand.  Microprobe XRF 
analysis of the Pt(II)-treated cells showed colocalisation of Pt and Br in the nucleus.[38-39]  
The authors concluded that the coexistence of Br (as a brominated amine ligand) and Pt 
confirmed the strongly held belief that the amine ligands are non-leaving groups of Pt(II) 
complexes.  In the second example, a Pt(IV) complex was prepared with a bromoacetate 
ligand in the axial position. A less intense Br map was obtained following treatment of the 
A2780 cells with the resultant Br-labelled Pt(IV) complex suggesting that reduction (and 
dissociation of the axial Br ligands) occurred prior to cell uptake.[38-39]  
Microprobe SRXRF imaging has been reported for thin sections obtained from a 
tumour harvested from a mouse 3 h after injection with the Pt anti-cancer agent, cis, trans, 
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cis-[PtCl2(OH)2(NH3)2)].
[38]  The study revealed Pt and Zn co-localization in one area of a 
section of the tumour which the authors interpreted as corresponding to only one cell.  The 
authors commented that identifying an appropriate sample area for imaging was an 
unexpected challenge.[38]  Nonetheless, this could be an important area for future studies for 
confirming the potential clinical usefulness of metal-containing therapeutics.   
Pt-Gd complexes have also been studied using microprobe SRXRF to determine the 
potential of these drugs for neutron capture therapy.  Since 157Gd possesses the largest 
effective nuclear cross-section, Gd(III) complexes are ideal agents for thermal neutron 
capture therapy employed for the destruction of tumour cells.[40]  As a mechanism of 
achieving this, Rendina and coworkers[40] designed and synthesised the Pt-Gd complex that 
incorporated the DNA intercalating moiety, [PtII(terpy)] (terpy = 2,2’:6’2’’-terpyridine). 
Microprobe SRXRF of individual A549 human lung carcinoma cells treated with the Pt-Gd 
complex (5 µM) for 24 h showed the colocalisation of the Gd and Pt in the Zn and P regions 
of the cell which define the nucleus.  Firstly, this result indicated that the Pt-Gd complex 
remained intact inside the cells.  Secondly, the finding that Gd and Pt accumulated in the 
nucleus was extremely important since the effectiveness of Gd(III) neutron capture therapy 
relies on the ability of the complex to localise in close proximity to critical cellular 
components of the cancer cells.[40]  In addition, statistical analysis of the intracellular K 
concentrations showed K increases of approximately 10× those of the control cells.  The 
authors attributed this to: (i) a possible activation of Na+/K+ ATPase; (ii) the direct interaction 
of the drug with potassium ion channels that effectively trap K+ in the cell; or (iii) the down 
regulation of potassium ion channel expression by targeting chromosomal DNA; although 
these hypotheses are yet to be confirmed.   
In an extension of the aforementioned medicinal chemistry approach, Rendina and 
coworkers[41] studied the cellular uptake of the Pt(II)-carborane complex where the same Pt 
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containing moeity, [PtII(terpy)], was attached to carborane, the latter being important as a 
boron neutron capture therapeutic agent.  In this instance, microprobe SRXRF was unable to 
show aggregation of Pt within the nucleus despite high levels of Pt found in the cells 
suggesting dissociation of the complex.[41] 
Arsenic-Containing Anti-Cancer Drugs 
Arsenic trioxide, marketed as Trisenox, was approved by the Food and Drug Administration 
in 2000 for the treatment of relapsed acute promyelocytic leukemia (APL).[42]  Its clinical 
administration has been associated with a 65-80% complete remission rate.[42]  This has 
prompted research into its mode(s) of action with the important goal of refining its 
administration and designing more efficacious As drugs for treatment of leukemias and solid 
tumours.[43-45]   
SRXRF has been used for monitoring As along the length of the hair of APL patients 
receiving Trisenox treatment.[46]  A beam (17 keV) of dimensions 10  3 µm2 was used to 
scan 30-µm thick hair sections covering a length of 5 cm (corresponding to a period of 5 
months hair growth).[46]  The results demonstrated a rapid response of As content in the hair 
that reflected the different treatment regimes.[46]  For instance, the As content in the hair 
showed expected fluctuations in a patient receiving non-continuous treatment over a period of 
2 months.[46]  In a more refined study led by the same author,[47] the X-ray beam (11.863 keV) 
was focussed to 1  3 µm2 dimensions using a KB mirror and a sampling interval of 7 h was 
used.  A steep increase in As content was observed within 24 h and reached more that half the 
maximum level.[47]  The results were in agreement with the pharmacokinetics of rapid As 
absorption and elimination.[47]  It was also observed that the As was distributed on the 
periphery of the cortex.[47] It was reported that this was similar to findings following external 
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As contamination of the hair which meant that one could not distinguish between ingested As 
or external As contamination based on its distribution through the cross-section of the hair.[47] 
Microprobe SRXRF has also been used to probe the mechanisms of Trisenox therapy.    
HepG2 human hepatoma cells were imaged following administration of arsenite (the soluble 
form of Trisenox).  Microprobe SRXRF showed that As accumulated in the euchromatin 
region of the cell nucleus following exposure to relatively high doses of arsenite (1 mM, 4 h, 
Figure 2).[32] This is consistent with As targeting DNA or proteins involved in DNA 
transcription.  Subsequent studies of HL-60 cells (APL cells) that had been administered 
therapeutically relevant doses of arsenite (10 µM, 4 h) have also shown As localisation in the 
nucleus, and in some cases the nucleolus.[48]  Intracellular concentrations were too low to 
confirm euchromatin localisation.[48]  The additional ability of microprobe SRXRF to 
quantify intracellular elements was also highlighted in the article whereby differences in the 
relative distributions of Ca within the nucleus and cytoplasm were correlated with As 
treatment.[32]  Increased nuclear Ca localisation was consistent with studies performed by 
Yee-Chien and Haimei[49] who showed that arsenite treatment of CHO-K1 cells also triggered 
Ca2+ accumulation.  The ability of the technique to monitor intracellular Ca2+ is important 
since the loss of Ca2+ homeostatic control is an indicator of apoptosis. In addition, toxic 
agents that cause depletion in GSH (as is the case for arsenicals) can cause a concomitant 
influx of Ca2+ and perturb the intracellular Ca distribution.[50] 
DNA Metallointercalator Agents 
Microprobe SRXRF has been important for the medicinal chemist for establishing “proof of 
concept” with respect to the mode of action of particular drugs.  A key example is the use of 
microprobe SRXRF for studying the uptake of metallointercalators to determine whether the 
complexes could target DNA, as intended in their design.[8]  Figure 3 shows the microprobe 
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SRXRF elemental maps of thin-sectioned cells obtained following the exposure of A549 lung 
cancer cells to cisplatin, or the metallointercalators, [56MESS] ([5,6-dimethyl-1,10-
phananthroline(1S,2D-diaminocyclohexane)platinum(III)]) or [Ni(phen)(dppz)]2+ (phen = 
1,10-phenanthroline, dppz = dipyrido[3,2-a:2’,3’-c]phenazine) for 4 h.  Thin-sections (1 µm) 
were mapped using a beam energy of 11.9 keV, focused to 0.2  0.15 µm2 using two zone 
plates, and using a 0.3 µm step size (Beamline 2-ID-D, Advanced Photon Source, Argonne 
National Laboratories).  The results were promising, since the microprobe SRXRF studies 
were the first to show that both Pt and Ni clearly localised in the cell nucleus following 
treatment with [56MESS] or [Ni(phen)(dppz)]2+, respectively.  Furthermore, it was clear that 
the localisation occurred in the heterochromatin region of the nucleus; i.e., in the vicinity of 
the densely packed DNA.[8]     
 
Metallocene Anti-Cancer Agents 
Microprobe SRXRF imaging of metallocene-treated V79 Chinese hamster lung cells was also 
performed since it has been reported (over 30 years ago) that metallocene dihalide complexes 
exhibit anti-tumour activity.[31,51] Complexes of the structure, Cp2MCl2 where Cp = 5-
cyclopentadienyl and M = Mo, Nb, Ti or V were studied to differentiate between the cellular 
targeting properties of the specific metal complexes since DNA (specifically nucleic acid rich 
regions of solid Erhlich ascites tumour cells) had been implicated as the primary target for 
Cp2TiCl2 and Cp2VCl2, with Cp2TiCl2 undergoing phase I and II clinical trials.  In contrast, 
no data existed for the Mo and Nb complexes and it was important to evaluate whether these 
complexes also possessed promising properties that warranted preclinical studies.[31]  
Unfortunately, microprobe SRXRF analysis of whole cells that had been treated with IC50 
concentrations of Cp2TiCl2 or Cp2VCl2 (100 µM and 10 µM, respectively, for 24 h) showed 
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only small increases in the Ti and V concentrations that were not considered significantly 
higher than the control cells using the Dunnett test.[31]  It was concluded that the intracellular 
concentrations must have been at the detection limit of the technique.  In contrast, significant 
increases in the intracellular Mo concentrations were obtained following treatment of the V79 
cells with Cp2MoCl2 (800 µM, 24 h) or Cp2Mo(SC6F4COONa)2 (800 µM, 24 h).
[31]  
Similarly, increased cellular Nb was detected in cells treated with Cp2NbCl2 (250 µM, 24 h).  
One of the greatest challenges of the study was the simultaneous detection of Mo and the 
important endogenous elements, given that the use of the 20.5 keV beam for detection of Mo 
resulted in poorer detection of the lower energy elements such as K, Cl, S, and P.[31]  In 
efforts to overcome this, dual mapping was performed at 10 keV and 20.5 keV using 
coordinates generated from alphabetised Finder grids.[31]  The resultant images showed 
colocalisation of Mo with K and Zn indicating the ability of Cp2MoCl2 to traverse the nuclear 
membrane and accumulate in the nucleus.[31] 
Nanoparticles and Nanoconjugates 
A rapidly emerging area of medicinal chemistry is the use of nanoparticles as direct 
therapeutic agents, drug delivery agents, and even diagnostic agents.[35,52-53]  Consequently, it 
is not surprising that microprobe SRXRF is becoming recognised as a technique for imaging 
intracellular nanoparticles in efforts to develop and confirm the capabilities of these 
agents.[35,52]   An exciting study has been reported by Paunesku et al.[52]  whereby they aimed 
to produce DNA-targeting TiO2 nanoparticles that could be excited, causing the 
electropositive holes of the semiconductor to be injected into the DNA, ultimately leading to 
DNA scission.  The important role of microprobe SRXRF was to establish whether these 
nanoparticles could be taken up by the cells and retained at their target DNA sequence.[52]  
Two DNA targets were studied, those of ribosomal RNA located in the nucleoli or the 
mitochondria.  It was shown that the different nanoconjugates were retained in detectable 
  13
quantities exclusively in the subcellular compartments that they were designed to target.[52]  
The authors also used microprobe SRXRF to show that inclusion of the contrast agent, 
Gd(III), into the nanoparticle to produce Gd(III)-modified DNA-TiO2 nanoconjugates, also 
resulted in a structure capable of specific organelle targeting.[54]  The interest in this result 
was that the complex possessed the added ability of being detectable by magnetic 
resonance.[54] 
 
Hard X-Ray Fluorescence Tomography. 
Plane-polarized XRF was proposed more than a decade ago for whole body imaging in order 
to take advantage of the fact that XRF is a non-invasive technique, capable of highly sensitive 
elemental analysis.[55]  A typical and highly desirable application of the technique was to 
image the platinum concentration associated with administration of the drug, cisplatin (or its 
transplatin analogues).[55]  The goal was to provide clinical information regarding its in vivo 
distribution and in so doing, assist in establishing dose-response relationships, for optimising 
and maximising therapeutic effect and minimising toxicity and cost.[55]  The minimum 
detectable concentration (MDC) increased with increasing depth of the tumour due to the 
attenuation effect.  Also the estimated MDC’s ranged from 5.6-38.1 ppm depending on the 
tumour depth (reported as 20-35 mm, respectively) and radiation dose applied.[55]  A number 
of challenges need to be overcome, however, before this becomes a more widely used 
technique. 
Microprobe XRF tomography has also been proposed as an exciting technique capable 
of 3-D imaging of trace elements in biological tissues and cells whereby sub-500 nm 
resolution XRF tomography is now possible. To date, SRXRF microtomography of bound Pt 
in DLD-1 human colon carcinoma spheroids has successfully monitored the depth of 
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penetration of cisplatin and three Pt(IV) complexes after 24 h exposure.[56]  The technique 
detected 10 ppm Pt in the cancer spheroids and showed enrichment of the Pt in the outer 
region (corresponding to the outer proliferative region) and uniform distribution deeper 
within the spheroid.[56]  In addition, the study showed poorer but similar penetration profiles 
of Pt(IV) complexes in comparison to cisplatin and represents an interesting future 
mechanism for studying the efficiency of other anti-cancer agents.[56]   
While not a medicinal chemistry application, de Jonge and Vogt[57] have performed 
higher resolution imaging of the whole diatom, Cyclotella meneghiniana, with 150-nm 
voxels over a 15-µm field of view.  An exciting prospect of the technique would be the 
incorporation of cryocapabilities which would enable the 3-D elemental analysis of frozen-
hydrated specimens.  Biological tissues and cells analysed by this technique would require 
minimal sample preparation, reducing concerns regarding the difficulties and artefacts 
associated with sample preparation and serial thin-sectioning.[57]  Despite the exciting 
promise of this technique, however, SRXRF microtomography has not yet found general 
application.  This is due to technical challenges combined with the required data acquisition 
times, for e.g. de Jonge and Vogt[57] calculated that analysis of a 10 µm3 specimen, performed 
at 30 nm resolution and 300 projections, would take 8 h.  The consequential use of a smaller 
sample size decreases the statistical power of the analysis and raises the question of the 
reliability of any conclusions.  Another challenge of SRXRF tomography, as alluded to in the 
case of whole body analysis, is self-absorption.[55,57]  Existing corrections of self absorption 
assume that the X-rays are confined to and are absorbed only by the voxels within the imaged 
specimen plane, which is unrealistic.[57]  As such further progress needs to occur before this 
technique can become routine and impact on medicinal chemistry research in the clinic.  
Fortunately, self-absorption will be less significant with smaller samples, such as individual 
cells. 
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X-Ray Absorption Spectroscopy 
XAS is an important tool for studying most elements of the periodic table and it has been 
extremely useful for studying transition metals and metalloids.  It is specifically useful for 
studying metals that are otherwise spectroscopically silent; i.e., those that possess filled or 
empty d-shells and have no spectroscopic signature.[58]  XAS is beneficial for the study of 
bioinorganic systems such as metal- and metalloid-containing drugs and enzymes since it is 
an extremely versatile and highly sensitive technique capable of providing information 
regarding metals in many physical states and chemical environments.[58-60]  The technique can 
be applied to bulk or microprobe analyses of samples which include: solids, biological 
solutions, electrophoresis gels, and healthy or diseased mammalian cells and tissue.[58-60]  
XAS, in contrast to XRF spectroscopy, cannot feasibly be performed using a laboratory 
X-ray source.  Instead the highly intense and tunable X-rays generated at a synchrotron are 
essential for XAS.[61]  The instrumental setup for XAS is shown in Figure 4 where it is 
apparent that XAS data can be collected in two modes: fluorescence mode or transmission 
mode.  Normally the technique is performed in transmission mode; however, in the case of 
trace elemental speciation such as those associated with biological samples, (i.e. those of 
dilute concentrations associated with proteins, bulk or single cells) the technique is often 
performed in fluorescence mode since it imparts greater sensitivity.[61] 
The principles for XAS are outlined briefly; however, the reader is referred to reviews 
for a more detailed description.[58,62-65]  An X-ray absorption spectrum is generated by 
subjecting the sample to a tuneable X-ray beam produced by a synchrotron source.  The X-
ray beam energy is swept across an energy range that encompasses the binding energy of the 
element of interest.  When the X-rays have sufficient energy to eject a core electron to an 
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orbital (that is partially filled or empty) or to the continuum, there is an abrupt increase in the 
absorption coefficient, which gives rise to the dominant feature of the XAS spectrum (Figure 
5) known as the “absorption edge”.[58]  The XAS spectrum can be divided into two main 
regions:  the X-ray absorption near edge structure (XANES) and extended X-ray absorption 
fine structure (EXAFS) regions, which contain extremely useful information regarding the 
local structural environment of the element of interest.[58]  
The XANES spectrum is typically defined as the region immediately within 
approximately 50 eV of the edge.  Key features of the XANES spectrum include the 
aforementioned edge, and the white line peak which occurs directly after the edge.  The 
XANES spectrum is sensitive to the oxidation state, the immediate coordinating atoms, and 
the electronic structure of the absorber atom.[58,62-63]  It provides information regarding the 
average coordination environment of the absorber atom and can be used to provide 
qualitative information.[58,62-63]  Typically, increases in the oxidation state are associated with 
increases in the energy associated with the absorption edge, since greater energy is required 
to eject the core electron.[58,62-63]  Caution must be used when relying on the spectral edge 
position to interpret the oxidation state, however, since the coordinating atoms also influence 
the edge energy.  For instance, while the oxidation state does not change, a slight decrease on 
the local charge of the absorber element brought about by coordination to a less electron-
withdrawing atom (e.g. S versus O) would result in a lower edge energy.[58]  In addition, and 
complementary to this, the edge energy can be influenced by the metal-ligand bond distance, 
with the edge energy expected to vary inversely with the square of the metal-ligand 
distance.[58]  Another factor that is observed in the XANES spectrum is that the features 
become broadened when the coordination environment becomes less symmetric, giving rise 
to a less intense white line.[58]  A typical example of this is the more symmetrical crystalline 
small-molecule models compared with their protein- or peptide- bound analogues.[58]  In 
  17
some cases a pre-edge peak is also observed. Weak pre-edge peaks for the K edge first row 
transition metals are observed for the forbidden (dipole selection rules) 1s  3d transition.  
They occur for metals that have an unfilled 3d shell and provide an indicator of coordination 
geometry. For instance, the centrosymmetric octahedral Cr(III) complex exhibits the weakest 
pre-edge feature, while the loss of centrosymmetry associated with trigonal bipyramidal and 
tetrahedral complexes is associated with an increase in the intensity of the pre-edge peak.[66-
69]  This phenomenon is due to the mixing of the 3d and 4p orbitals and direct quadrupolar 
coupling.[58,66]   
The EXAFS spectrum extends to higher energies and contains more subtle features 
(Figure 5). It results from the interaction of the ejected electron with the surrounding atoms 
and is distinguished by a wavelike structure indicative of the constructive and destructive 
interference from which it is generated.  For more detailed information regarding the 
principles of EXAFS the reader is referred to the cited reviews.[8,58,64-65]  
Both XANES and EXAFS have played essential roles in the analysis of proteins and 
enzymes in cells. Micro-XANES/EXAFS utilises focusing devices (KB mirrors or zone 
plates) that focus the beam to micron or submicron dimensions, enabling analysis of cellular 
and subcellular structures.  To date micro-XANES analysis has provided information 
regarding metals associated with diseased states, such as Fe(II/III) located in the neuronal 
cells of subjects exhibiting Alzheimers and Parkinsons diseases,[70] Cu(I)/Cu(II) in 
dopeminergic cells associated with Parkinson’s disease, and Zn concentrations associated 
with prostate cancer.[70]  The focus of the following sections, however, is on the use of 
XANES and EXAFS (and the microprobe applications of these) to study the chemical 
structure of therapeutic agents prior to and after cell uptake in order to probe their 
biotransformations within cells. 
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Platinum-Containing Anti-Cancer Agents 
Both XANES and EXAFS have been used by medicinal chemists to characterise metal-
containing drugs in solution, formulations, and biological media.  Some of the most 
prominent studies include those associated with the anti-cancer drug, cisplatin.  Solutions of 
the platinum-containing drug, cisplatin,[71] and its derivative, oxaliplatin,[72] have been 
analysed by bulk XAS to confirm the presence of axial water ligands.  Bulk XAS has also 
been used for the development of controlled release drug delivery systems by confirming the 
integrity of drugs in the delivery agent; a specific example being the use of XAS to confirm 
that the structure of cisplatin did not alter following its incorporation into poly(ethylene 
oxide) gel.[73]  
Hambley and coworkers[33,74-75] used bulk XAS to determine the ability of Pt-treated 
cancer cells to reduce Pt(IV) complexes to the potentially more active Pt(II) anti-cancer 
agents. Predictably, the position of the edge assisted in the differentiation (2.2 eV difference) 
of Pt(II) from Pt(IV).[33,74]  So too did the ratio of the intensity of the white line peak to the 
post-edge region.[33,74]  In recent efforts to try to combat cisplatin resistance, Hambley and 
coworkers[75] prepared monomeric Pt(IV) analogues, [trans,mer-[PtCl(OH)2] and [trans,mer-
[PtCl(dien)], of the potent polynuclear platinum complex, [trans-PtCl(NH3)2)2{µ-trans-
Pt(NH3)2(NH2(CH2)6NH2)2}]
4+, since the latter complex had been withdrawn from phase II 
clinical trials due to side effects (despite earlier promise).[75]  Human ovarian A2780 
carcinoma cells were treated with the Pt(IV) drug and analysis of the XANES spectra with 
respect to the standard curve, prepared from the ratio of the peak height to the post-edge 
intensity for known ratios of Pt(II) to Pt(IV), was performed.  It was found that 38% of the 
drug had reduced to Pt(II) in the first 2 h while most of the drug (87%) had converted to 
Pt(II) within 24 h.  They concluded that the improved intracellular stability of the triammine 
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complex highlights the importance of preparation and testing of the Pt(IV) polynuclear 
complex.[75]  
Arsenic-Containing Anti-Cancer Agents 
In a pharmaceutical-directed study, Nicolis et al.[76], used XAS to characterise arsenic in the 
injectible arsenic trioxide formulations used to treat APL patients.  Unsurprisingly, XANES 
spectroscopy showed that the As species was As(III) while EXAFS analysis indicated that the 
arsenic was coordinated to three oxygen atoms at a distance of 1.779 Å, similar to arsenous 
acid.[76]  Nicolis, et al.[47] also performed XANES studies of As in the hair of APL sufferers 
following Trisenox administration.  They reported that the As was not S-bound but was O- or 
N- bound.  They attributed this finding to the fact that the cysteine residues of keratin are 
engaged in cystine sulphur bridges.[47]  
Multiple linear regression analysis of XANES spectra and EXAFS analysis of spectra 
obtained from arsenite-treated HepG2 human hepatoma cells (100 µM, 4 h) were employed 
to shed light on the As metabolites formed following high dose exposure.  The predominance 
of As tris-sulfur species provided increased credence to the likelihood that the dominant 
interactions of As occurred with nuclear proteins and potentially act as a key factor in As-
induced cancer toxicity.[32]   
Bacquart et al.[77] performed microprobe XANES of As located (by microprobe 
SRXRF) in the nucleus, cytosol and mitochondrial network of arsenic trioxide-treated human 
ovarian adenocarcinoma (IGROV1) cells.  The instrumental set-up involved the use of a 
liquid nitrogen cryo-stream to reduce radiation damage to the sample.  It was found that the 
predominant species in the IGROV1 cells, and that responsible for toxicity, was As(OH)3 
since metabolism was negligible in the cell line.[77]  In contrast, microprobe-XANES analysis 
of HepG2 cells treated with As(OH)3 showed small edge energy shifts of the As XANES 
  20
spectra that were dependent on the organelles (average edge energies: arsenic trioxide, 
11871.5 eV; nucleus, 11870.7 eV; cytosol and mitochondrial network, 11871.2 eV) 
indicating differences in As speciation.[77]  Exposure to low concentrations of arsenite (10 
µM, for 24 h vs 100 µM, 4h in the study described above)[32,77] also resulted in predominance 
of As(III), although there was some evidence of mixed valence As (As(III)/As(V)) in the 
nucleus of one of the nine cells analysed.[77]  
Other Anti-Cancer Agents 
XANES analysis of intracellular cobalt has been important for the development of cobalt 
complexes as potential hypoxia-activated prodrugs.[78-80]  The concept was to exploit the 
hypoxic nature of tumours whereby the inert Co(III) complexes could be reduced to the labile 
Co(II) complexes in the reducing environment, and subsequently release an active anti-cancer 
agent.[78-80]  The XANES studies involved the systematic study of a mixture of Co(III) and 
Co(II) complexes to differentiate between the oxidation states.[78]  It was noted that the 
analysis of Co in cells was complicated by changes in the coordination sphere of Co(III) 
complexes, and that XANES was useful for monitoring the oxidation state as long as the 
ligand exchange reactions of Co(III) were slow relative to the reduction to Co(II).[78]  While 
the XANES of intracellular Co obtained from [Co(diNOsar]Br3-treated cells reflected that of 
the solution spectra of the complex, it was found that the spectra obtained from [Co(acac)3]- 
and [Na[Co(acac)3]-treated cells reflected a mixture of intracellular products. indicating a loss 
of the carrier ligands .[80] 
 EXAFS in conjunction with the new synchrotron based technique, nuclear resonance 
vibrational spectroscopy (NRVS), and density functional theory calculations was used to 
probe the anti-cancer mechanisms of the glycopeptide, bleomycin.[81]  Bleomycin is an 
effective chemotherapeutic agent used to treat Hodgkins lymphoma and head, neck, and 
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testicular cancers. It is believed to complex to Fe in vivo to facilitate DNA double strand 
scission via a reaction of FeIIIBLM with O2 and an electron, or through a shunt reaction 
between FeIIBLM and H2O2.
[81]  Following the study, it was concluded that the active species 
were (BLM)FeIII-OH and (BLM)FeIII(1-OOH) and that direct H-atom abstraction is the 
thermodynamically favoured pathway over other proposed pathways.[81] 
Anti-Malarial Drugs 
EXAFS of Fe has also been conducted to improve the understanding of the mechanism of 
action of the anti-malarial drug, chloroquine.[82]  It is known that malaria parasites are 
susceptible to quinoline based drugs only at the time of hemoglobin degradation and 
production of malarial pigment.[82]  The parasite digests the peptide chains of the host’s 
hemoglobin and needs to dispose of the remaining heme to avoid toxicity and death of the 
parasite.  It is believed that quinoline drugs complex to the resultant heme and prevent their 
disposal.  Walczak et al [82] claimed that, it was impractical to directly study infected blood 
samples from patients treated with chloroquine, given the fact that there is Fe associated with 
hemoglobin as well as the heme remaining from the parasites’ digestion.  Consequently, they 
performed XAS of the synthetic substitute, mesohematin anhydride, in acidic solvent (to 
simulate the parasite’s food vacuole) in the presence of the drug. [82] They observed 
differences between the synthetic equivalent of hemozoin in the powder state compared to the 
aqueous state (in acetic acid and water) at different concentrations that mimicked the 
physiological condition of the parasite’s food vacuole.  Additional changes were also 
observed following the addition of the anti-malarial drug, chloroquine.[82] 
Anti-Inflammatory Agents 
One of the earliest medicinal chemistry uses of XAS was the study of the biotransformation 
products of gold-based rheumatoid arthritis drugs.[83]  Aurosomes isolated from Sprague-
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Dawley rats that had been injected (intraperitoneally) with sodium gold(I)thiomalate (0.4 mg 
Au/kg, weekly for 20 weeks) or gold(III) tetrachloride (35 mg Au/kg, single dose) were 
analysed using XANES.[83]  XANES spectra revealed that the gold associated with the 
aurosomes following treatment with sodium gold(I)thiomalate was Au(I).[83]  In addition, 
Au(I) was also identified in the aurosomes of rats that had been treated with gold(III) 
tetrachloride indicating the in vivo reduction of Au(III).[83]  EXAFS analysis revealed that the 
Au resulting from administration of gold(I)thiomalate was coordinated to two sulfur atoms 
which were believed to be of cysteine (protein) or glutathione origin.[83]  While reported in 
the context of Au anti-proliferative agents, Messori et al. recently performed XAS studies of 
the interactions of auranofin with the human plasma proteins, bovine serum albumin and 
serum apotransferrin.[84]  The Au(I) oxidation state was conserved during protein binding and 
the mechanism was believed to occur through release of the thiosugar ligand to facilitate 
replacement with a thiol or thioether from the protein.[84]   
The use of XAS for the development of copper containing NSAIDs, such as 
[Cu2(indo)4L2], indo = (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetate) and L 
= solvent ligands, played a crucial role in the development of veterinary and human 
nonsteroidal anti-inflammatory formulations, the latter proceeding to human clinical trials.[85]  
XAS was used to explore the chemical and physical properties of the formulations with 
emphasis on modelling the dimeric Cu2O10C8 core in the dimeric Cu(II) complex and 
examining any changes in it as a result of changes in the axial ligands.[85]  The flexibility of 
the technique for analysing injectable formulations, gels, ointments, and pastes highlights its 
usefulness for characterising pharmaceuticals for registration.  Similarly, EXAFS was also 
applied for the successful characterisation of mononuclear and dinuclear zinc-indomethacin 
complexes.[86] 
Ruthenium Anti-Metastatic Agents 
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Emerging drugs (in phase I clinical trials) such as the potential Ru(III) chorido-indazole anti 
cancer drug (KP1019) and the anti-metastatic agent, NAMI-A,[87-88] have been analysed in 
cell culture media, blood serum and cultured mammalian cells to understand the 
transformations that occur to the metal centre.  Lay and coworkers[89] isolated Ru(III)-BSA 
complexes by gel-filtration chromatography, freeze-dried the product and analysed it by 
XAS.[89]  The resultant spectra were compared with the parent Ru(III) complex, and model 
Ru(III) complexes containing predominantly Cl, NH3, or CH3COO
 ligands.[89]  Linear 
regression analysis of the post-edge regions of the XANES spectra revealed that the Ru(III)-
BSA spectrum was best characterised by a model consisting of 65% Ru bound to N, and 35% 
Ru bound to O, suggesting replacement of the original Cl ligands with protein N-donors and 
carboxylato residues.[89]   The authors concluded that the XAS evidence, suggesting that 
>90% of the Ru(III) complex binds to blood albumin, is consistent with its low toxicity but 
high anti-metastatic efficacy.[89] 
Dietary Supplements 
Multiple linear regression analyses of XANES spectra have been used for characterisation of 
Cr(III) anti-diabetic supplements including [Cr3O(OCOEt)6(OH2)3]
+, [Cr(pic)3] (pic = 2-
pyridinecarboxylato) and trans-[CrCl2(OH2)4]
+ (introduced as CrCl3.6H2O) in biological 
fluids and in cultured cells.[90] It was found that [Cr3O(OCOEt)6(OH2)3]
+ and [Cr(pic)3] 
underwent extensive ligand exchange reactions in solutions that simulated gastric and 
intestinal conditions and in the presence of blood serum and cell culture medium.[90]  The 
resultant products were identified as Cr(III) complexes coordinated to hydroxo and amino 
acid ligands.[90]  Concern was raised over the finding that reactions of [Cr(pic)3] with serum 
enhanced its propensity to be converted to carcinogenic Cr(VI) by biological oxidants.[90]  
  24
The speciation of common selenoamino acid supplements, selenomethionine (SeMet) 
and Se-methylselenocysteine (MeSeCys) in A549 human lung cancer cells has also been 
investigated using XAS.[91]  The value of this research stems from the fact that the essential 
element, Se, has been linked to reductions in the cancer incidence and mortality when 
administered at supranutritional doses.[91]  MeSeCys is believed to be the more effective 
chemopreventative agent of the two complexes since MeSeCys is known to produce MeSeH 
more efficiently than SeMet.[91]  Linear combination fitting of the XAS spectra of the Se 
standards to those obtained from the cell pellets treated (24 h) with the supplements showed 
that Se was found exclusively in the carbon bound form in SeMet-treated cells while a 
diselenide component was also identified in MeSeCys-treated cells, indicating that there was 
a difference in the metabolism of the supplements.[91]  It was suggested that the presence of 
the diselenide component in the MeSeCys-treated cells may be due to the cleavage of 
MeSeCys by -lyase to produce the active anti-carcinogenic compound, MeSeH.[91]  
 
Synchrotron Radiation – Fourier Transform Infrared Microspectroscopy 
The application of vibrational spectroscopy for the detection of disease in human tissue and 
cells commenced in the early 1990’s and escalated following the development of lab-based 
and later, synchrotron radiation-based infrared microspectroscopy.[92]  There have since been 
significant developments towards disease diagnosis, improvements in the understanding of 
disease progression and validations of hypotheses regarding diseases such as prostate,[93] 
skin,[94] colon,[95] cervical,[94,96] and breast cancers,[97] melanoma,[98] leukemia,[99] 
transmissible spongiform encephalopathies/prion diseases,[100] Alzheimers disease,[101-102] 
diabetes,[103] malaria,[104] ophthalmic disorders,[105] and arthritic disorders.[94,99]   
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The usefulness of SR-FTIR microspectroscopy derives from the fact that the IR source 
is 10-1000 times more brilliant than the conventional globar source.[106-107]  This equates to 
superior signal to noise ratios in the resultant spectra, improving acquisition times and spatial 
resolution, both of which are important for analysing biological samples.[92,106]  As such, 
recent attention has been focussed on the use of SR-FTIR microspectroscopy for the study of 
biomolecular changes that occur following the administration of drugs or potential 
therapeutic agents in diseased cells.[92,108-112]  Importantly, macromolecules associated with 
biological samples produce signature IR bands that can be readily discerned from the IR 
spectra.[94,99,113-114]  Typical spectral features include: amide I ( 1650 cm1) and amide II ( 
1549 cm1) bands representative of proteins; symmetric (1080 cm1) and anti-symmetric 
PO2
 (1232 cm1) bands associated with DNA; C-H stretches of –CH3 (as 2955 cm1) and 
–CH2 (as 2850 cm1), the ester band (1740 cm1) and the C-O-P (1080 cm1) band 
associated with lipids/phospholipids; and C-O stretches (1050 cm1) of carbohydrates.[94,99,113-
114]  In addition, changes in the average protein secondary structure can be detected by 
analysing the components of the amide I band.  For instance, specific secondary structural 
assignments include:  -helices (1645-1662 cm1), -sheets (1613-1637 cm1), turns (1662-
1682 cm1) and random coils (1637-1645 cm1).[99,113,115-117]  
A recently emerging medicinal chemistry application of SR-FTIR microspectroscopy is 
the analysis of fixed and live cancer cells to detect biomolecular changes that occur following 
drug treatment.  The interest in the use of this technique stems from an urgent demand for the 
development of accurate and cost-saving analytical techniques that can be applied to the 
screening of new drug candidates.[109]  The analysis involves the collection of spectra from 
large numbers of cells (generally >100 cells per sample) following exposure to the 
therapeutic agent, and the objective analysis of the resultant data through statistical 
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procedures such as principal component analysis (PCA) and hierarchical cluster analysis.[92]  
While changes in spectral features can often be visually observed in average spectra, tools 
such as PCA remove subjectivity and add credence to the evaluation of any biomolecular 
differences/similarities in the spectra of cell or tissue samples.[118]  SR-FTIR can be used for 
mapping individual cells and tissues;[119-120] however, this is diffraction limited and noise 
becomes apparent at approximately 1000 cm1 when an aperture of 5 µm2 or smaller is 
used.[106]  Currently, there a a number of new promising developments in progress to try and 
overcome this limitation as described within the cited review.[24] 
One of the most important challenges of SR-FTIR analysis of single cells is overcoming 
issues of highly distorted baselines, and derivative-like peak shapes, which are associated 
with small (<10 µm) cells and specifically affect strong bands such as the amide I band.[92,107]  
In an effort to try to separate biochemical-induced effects from those of the physical shape 
and size of the cells that lead to the IR baseline abnormalities, Gardner and coworkers have 
developed correction algorithms that reduce the distortions caused by resonant Mie 
scattering.[92,107,121]  These have been implemented in a number of studies.[92,122-124] 
Anti-Cancer Agents 
A typical example of the use of SR-FTIR microspectroscopy for monitoring therapeutic 
effects was the study of the spectral changes on non-small cell lung cancer cells (Calu-1) 
following administration with cytostatic doses (0.1-100 nM) of the anti-tumour drug, 
gemcitabine, for 24-72 h.[108]  The study showed complimentarity between spectra obtained 
from individual cells using SR-FTIR versus those obtained from bulk cell populations using a 
conventional laboratory IR.[108]  Hierarchical cluster analysis of spectral windows showed 
dose- and time-dependent effects of the drug.  Draux et al.[108] reported increases in the 
molecular vibrations corresponding to characteristic bands of proteins and RNA and it was 
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concluded that these IR changes may be related to the molecular mechanism of the cytostatic 
drug and the accumulation of the cells in G1 phase.[108]  
Bellisola, et al.[109] performed SR-FTIR microspectroscopy of chronic myeloid 
leukaemia (K562) cells to identify signatures of apoptosis following administration of a drug 
that directly targets the BCR/ABL oncogene protein, imatinib mesylate (4-[(4-
methylpiperazin-1-yl)methyl)-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2yl)amino]-
phenyl]benzamide), and a drug that indirectly targets the BCR/ABO oncogene protein, 
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride).  The authors 
performed complimentary techniques such as Western Blotting analysis and were able to 
identify and cross-validate some IR signatures induced by the imatinib mesylate in the K562 
cells.[109]  For instance, they concluded that significant changes that occurred in the interval 
1290-900 cm1 and in particular between 940-900 cm1, were associated with changes in the 
PO stretching mode in the phosphorylated proteins.[109]  This was significant because the drug 
was known to cause a rapid decrease of protein tyrosine phosphorylation.[109] 
Mantsch and coworkers[125] have also used SR-FTIR microspectroscopy for the 
detection of apoptosis in K562 cells and the T-lymphoblastic cell line (CEM cells), with the 
aim of determining its feasibility as an indicator of chemosensitivity of leukaemia cells 
isolated from individual patients.  They noted greater changes in the CEM cells (52.8%) 
versus K562 cells (15.67%) after 24 h exposure to the drug, etoposide, and found excellent 
correlation with the percentage of apoptosis observed by flow cytometry results.[125]  It was 
also concluded that SR-FTIR microspectroscopy was able to detect apoptosis after 4 h 
compared to 6 h using flow cytometry.[125]   
SR-FTIR microspectroscopy was performed on A2780 ovarian cells that had been 
treated with a new di-gold(I) organometallic complex, [1,3-(Ph3PAu)2C6H4], that was found 
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to exhibit cytotoxic activity in vitro.[92]  The interest in the drug stemmed from the fact that it 
induced little to no resistance against cisplatin resistant cells which implied that the drug 
acted by different mechanism(s).[92]  Following the application of Mie scatter correction, 
there was significant differentiation between the cell spectra obtained on treatment with 
different drugs which fitted with different in vitro cell culture behaviour.[92]  PC2 differences 
were observed following the comparison of the control versus cisplatin or cisplatin versus 
[1,3-(Ph3PAu)2-C6H4]-treated cells.
[92]    
Photodynamic Therapeutic Agents 
Another example where SR-FTIR has been used for the evaluation of therapeutic effects 
includes the area of photodynamic therapy (PDT).[111]  PDT is based on the interaction of 
light with a photosensitiser which, in turn, results in the production of radical species that 
induce the death of cells in close proximity.  For instance, PDT has potential for treatment of 
cancerous cells (e.g., skin cancers) and infectious organisms.[111]  Chio-Srichan et al.[111] 
studied the effect of Hypocrellin A in HeLa cells as a function of incubation time since it 
reportedly possessed anti-cancer activity when irradiated with light.  PCA of the SR-FTIR 
spectra obtained from cells administered Hypocrellin A followed by irradiation (10 J cm2 
dose at 460 nm) revealed changes in the protein secondary structures, whereby a shift of the 
amide I band from 1650 cm1 to 1630 cm1 was attributed to a contribution of increased 
secondary -sheet structure.[111]  Decreases in the peaks in the region 1000-1300 cm1, 
associated with DNA, were also observed.[111]  This was attributed to a higher optical density 
of condensed DNA, consistent with transmission electron microscopic evidence.[111] 
The PDT potential of 4,5-benzoindotricarbocyanine (indocyanine green, ICG) as a 
treatment for human melanoma was also assessed by SR-FTIR microspectroscopy.[112] 
Previously, the poor success of PDT with melanomas was believed to stem from their high 
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content of melanin which acts as a screen for white light.  Consequently, ICG was proposed 
since it absorbs light in the range 700-800 nm, where melanins do not absorb.  SR-FTIR 
analysis was performed on human skin melanoma cells (Sk-Mel-28) treated with ICG 
followed by PDT.[112]  Cluster analysis of the resultant IR spectra revealed a decrease in the 
nucleic acid phosphate absorption modes at 1240 and 1180 cm1 in the ICG/PDT-treated cells 
which was consistent with DNA fragmentation of the apoptotic cells.[112]  Additionally, there 
were protein conformational changes associated with protein denaturation and increases in 
the lipid bands suggesting redistribution of the phospholipids within the cell membrane (i.e., 
externalisation of phosphatidyl serine).[112]    
Live Cell SR-FTIR Microscopic Analysis 
Although an experimental challenge, live cell analysis under aqueous media is desirable as it 
removes the potential for spectral artifacts resulting from fixation procedures and provides 
the added advantage of allowing real time analyses.[110,126-128]  SR-FTIR microspectroscopy 
was used to analyze live leukemia cells following their exposure to Trisenox, administered 
in the form of sodium arsenite (100 µM).[110]  The procedure involved the use of a 
demountable liquid cell comprising a 1-mm thick CaF2 window onto which a spacer had been 
patterned by polymer spin coating and UV photolithography, and an upper 0.5-mm thick 
CaF2 window (Figure 6A).
[110,126]  The two windows were held tightly together in a Thermo 
micro compression cell (Figure 6B) in order to reduce the aqueous sample volume. The 
design of the sample holder enabled the collection of high quality spectra from a solution that 
was less than 20 µL.  This meant that the spectra were not dominated by OH deformation 
(Figure 6D).[110,126]  Exposure of the HL-60 cells to the anti-leukemia drug resulted in 
significant spectral differences within 40 min exposure. The most prominent differences (as 
determined by the second derivative spectra and PCA) occurred in the protein region of the 
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spectrum, where the dominant contribution to the amide I band shifted from 1639 cm1 (-
sheet) in the control cells to 1650 cm1 (-helix) in the arsenite-treated cells.[110]  The overall 
results of this study indicated that the mechanisms of action of arsenite-induced toxicity 
involved alterations to the protein structure and interactions with DNA.[110]   
One of the drawbacks of the demountable liquid cell described above was the slow loss 
of the media, over the period of 2 h, limiting long term exposures and data collection.[110,126]  
Subsequent improvements to the design have been made whereby the lithography fabricated 
spacer has been changed from a single outlet channel to three zig-zag channels (Figure 6C), 
which effectively slow down the loss of the solution.[126]  An alternative live cell sample 
holder was reported by Holman et al.,[128] which was a custom made on-stage mini incubator.  
It allowed in situ SR-FTIR collection of spectra from cells while maintaining a proper 
moisture and growth environment.[128]  Clearly, the success of such devices, which enable 
long term monitoring of the sample, will provide invaluable insights into the mechanisms and 
kinetics of drug-induced cell modifications. 
 Combination of SR-FTIR and Fluorescence Microscopy for Simultaneous Analysis 
The combination of SR-FTIR microscopy with fluorescence microscopy at the same 
beamline was documented in 2002.[102]  For the first time, an IR microscope had been 
modified to allow simultaneous fluorescence sample visualisation and IR analysis.[102]  The 
capabilities were exploited for experiments ranging from studies of osteoporosis, to 
Alzheimer’s diseased brain tissue, to cell apoptosis.[102]  The most sophisticated of the 
experiments was the study of the effect of the drug, nandrolone decanoate (an anabolic 
steroid that enhances bone density in osteoporotic women) in female monkeys that had 
undergone ovariectomies to induce osteoporosis.[102,129]  The monkeys were administered 
different fluorochrome labels at 1 (calcein) and 2 years (alizarin) after the ovariectomy, to 
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identify the new bone using fluorescence microscope.  The areas were analysed by SR-FTIR 
microspectroscopy and the phosphate/protein ratio was studied with reference to control 
monkeys.  The results showed a reduced rate of bone mineralisation in ovariectomised 
monkeys versus the control.  Furthermore, the mineralisation was also effected in the 
monkeys treated with nandrolone decanoate.[129] 
Conclusions 
It is clear that synchrotron radiation techniques have provided, and will continue to provide, 
important information to the medicinal chemist.  Microprobe SRXRF has proven itself as a 
technique for providing unequalled information regarding the distribution of metal and 
metalloid-containing drugs in cells and tumours at subtoxic and therapeutic doses.[8,26,31-
32,38,40-41,56]  Targets such as the nucleus,[26,38] including the euchromatin[32] and 
heterochromatin[8] regions, nucleoli,[32,48,52] membranes, and mitochondria[52] can be 
identified as sites of localisation following studies of existing and potential therapeutic and 
diagnostic agents.  The technique has been invaluable for confirming theories of drug actions 
(namely, the coordinative action of cisplatin and its analogues)[38-39] and for confirming 
concepts associated with the modes of action of designed therapeutics (namely, confirmation 
of drug penetration to the site of dense DNA).[8,40]  In addition, microprobe SRXRF has been 
used to determine whether potential therapeutic agents remain intact[40] or dissociate 
following cell uptake.[41]  The additional quantitative analysis of endogenous elements has 
become significant for probing changes to the homeostasis of the cells as exemplified in the 
studies of Ca changes associated with As uptake,[32] and intracellular K fluctuations following 
the uptake of Pt-Gd complexes.[40]  Detection of subtle changes in the concentrations and 
distributions of endogenous cations or anions can provide invaluable information regarding 
apoptosis and other modes of drug action. 
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XAS has played a pivotal role in the structural analysis of therapeutic agents.  It has 
been essential for confirming/elucidating the structure of newly prepared complexes,[85] and 
determining the fate of these complexes in biological solutions.[89]  Not only has this given 
insight into the mechanisms of their action, but it has also helped to understand why some 
therapeutic agents might, or have shown, lower than expected efficacy.[85]  The use of XAS 
for bulk cell analysis has provided insight into the metabolism of therapeutic agents and 
supplements[32,77,91] informing the medicinal chemist of expected products in vivo to be 
exploited for further design purposes or for progression to animal studies and human clinical 
trials.  
Finally, the use of SR-FTIR microspectroscopy for studying the biomolecular effects of 
drugs in vivo and in cell culture has become prominent in the last 5 years with studies of anti-
cancer drugs,[92,108-109,125] osteoporosis drugs,[102] and photodynamic therapeutics[111-112] 
showing distinguishable biomolecular changes.  Issues associated with Mie scatter distortion 
of the spectra are being addressed,[92,122-124] and the technique is being critically assessed with 
a goal to using it for preclinical and clinical evaluation of drug candidates.[92,109,125]  Clearly, 
major advances in the design of live cell sample holders will also aid in the study of 
therapeutic agents.[110,126-128]      
In conclusion, it is anticipated that these synchrotron radiation spectroscopic techniques 
will play a major role in medicinal chemistry in the future especially as improvements in the 
instrumentation associated with the techniques evolves. 
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Figure Captions 
 
Figure 1.  Physical events associated with XRF spectroscopy that lead to the emission of 
characteristic X-rays.  Allowed electronic transitions that give rise to characteristic X-
ray lines are shown.  E = Energy; BE = Binding Energy. Reprinted from: Chapter 11. 
Synchrotron radiation X-Ray spectroscopy for investigations of intracellular 
metallointercalators: X-ray fluorescence imaging and X-ray absorption spectroscopy, 
Dillon, C. T. in Metallointercalators. Synthesis and techniques to probe their 
interactions with biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.1, p 275, 
Springer-Verlag/Wien, with kind permission from Springer Science and Business 
Media B.V. 
Figure 2. Microprobe SR-XRF maps of P, S, Cl, K, Ca, Zn, Cu and As obtained from a thin-
sectioned HepG2 cell that had been treated with arsenite (1 mM, 4 h).  Scan 
dimensions: 20 × 20 µm, stepsize: 0.3 µm, dwell time: 3 s/pt. Reprinted with 
permission from:  Munro, K. et al.; Chem. Res. Toxicol., 2008, 21, 1760-1769. 
Copyright 2008 American Chemical Society. 
 
Figure 3. Microprobe SRXRF elemental maps of A549 cells following treatment with : (A) cell 
media only; (B) Ni(phen)2(dppz)]
2+
 (960 µM), or (C) [Pt(56MESS)] (490 µM).  The 
elements are specified at the bottom of each column.  Operating conditions include:  
Beam energy = 11.9 keV, Beam size = 0.2 µm × 0.15 µm; Stepsize = 0.3 µm; Dwell 
time = 3 s/pt and Scan dimensions (H × V) = (A) 9 µm × 10 µm; (B) 14 µm × 14 µm 
(C) 10 µm × 10 µm. Reprinted from: Chapter 11. Synchrotron radiation X-Ray 
spectroscopy for investigations of intracellular metallointercalators: X-ray 
fluorescence imaging and X-ray absorption spectroscopy, Dillon, C. T. in 
Metallointercalators. Synthesis and techniques to probe their interactions with 
biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.5, p 287, Springer-Verlag/Wien, 
with kind permission from Springer Science and Business Media B.V. 
Figure 4. Experimental setup employed for XAS data collection.  Reprinted from: Chapter 11. 
Synchrotron radiation X-Ray spectroscopy for investigations of intracellular 
metallointercalators: X-ray fluorescence imaging and X-ray absorption spectroscopy, 
Dillon, C. T. in Metallointercalators. Synthesis and techniques to probe their 
interactions with biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.7, p 293, 
Springer-Verlag/Wien, with kind permission from Springer Science and Business 
Media B.V. 
Figure 5. Typical XAS spectrum defining the XANES and EXAFS regions and showing typical 
spectral features. Reprinted from: Chapter 11. Synchrotron radiation X-Ray 
spectroscopy for investigations of intracellular metallointercalators: X-ray 
fluorescence imaging and X-ray absorption spectroscopy, Dillon, C. T. in 
Metallointercalators. Synthesis and techniques to probe their interactions with 
biomolecules, (Ed. J. Aldrich-Wright) 2011, Figure 11.6, p 290, Springer-Verlag/Wien, 
with kind permission from Springer Science and Business Media B.V. 
  
 
Figure 6. Live cell sample holder (A-C) including the two spacers (A and C) and the entire 
holder (B).  Resultant live cell spectra are shown (D) and include SR-FTIR averaged 
spectra from HL60 control cells (40 min, −, n=23) and HL60 cells treated with 100 µM 
arsenite: 40 min (−, n=20), 60 min (−, n=20), 100 min (−, n=18) and 120 min (− , 
n=15).
[92,107]
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